Progress of tolvaptan in treating heart failure
10.3760/cma.j.issn.0254-9026.2016.02.025
- VernacularTitle:托伐普坦治疗心力衰竭的研究进展
- Author:
Xue LI
;
Bei LAI
;
Dahai HUANG
;
Hong SHI
- Publication Type:Journal Article
- Keywords:
Tolvaptan;
Heart failure,congestive;
Hyponatremia
- From:
Chinese Journal of Geriatrics
2016;35(2):214-216
- CountryChina
- Language:Chinese
-
Abstract:
Tolvaptan is a novel oral selective arginine vasopressin V2 receptor antagonist.Tolvaptan improves heart failure signs and symptoms without serious adverse events.Tolvaptan has no effect on all-cause mortality and cardiovascular death or admission rate for heart failure.But in heart failure patients with hyponatremia,tolvaptan can decrease cardiovascular death and admission rate for heart failure.
